ArticleNeurobiology of aging2021
Molecular imaging of beta-amyloid deposition in late-life depression.
Article in Neurobiology of aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Depression in older adults with epilepsy: Pathophysiology and management considerations.Epilepsy & behavior : E&B · 2025Review
- Multimodal investigation of neuropathology and neurometabolites in mild cognitive impairment and late-life depression withNeurobiology of aging · 2024Article
- The utility of PET imaging in depression.Frontiers in psychiatry · 2024Review
- The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Molecular imaging of the association between serotonin degeneration and beta-amyloid deposition in mild cognitive impairment.NeuroImage. Clinical · 2023Article
- Assessing the Role of Past Depression in Patients with Mild Cognitive Impairment, with and without Biomarkers for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Article
- Associations of depressive symptoms with white matter abnormalities and regional cerebral blood flow in patients with amnestic mild cognitive impairment.Geriatrics & gerontology international · 2022Article
- Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study.Translational psychiatry · 2022Article
- Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment.Brain communications · 2022Article
- Pathomechanisms of Vascular Depression in Older Adults.International journal of molecular sciences · 2021Review
- Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares.Translational psychiatry · 2021Article
- The functional role of the pulvinar in discriminating between objective and subjective cognitive impairment in major depressive disorder.Alzheimer's & dementia (New York, N. Y.)Article
- Differentiating MCI from depression through verbal memory scores.Alzheimer's & dementia (New York, N. Y.)Article
- The Interface between Depression and Alzheimer's Disease. A Comprehensive Approach.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Late-life depression (LLD) is associated with an increased risk of all-cause dementia and may involve Alzheimer's disease pathology. Twenty-one LLD patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for a current major depressive episode and 21 healthy controls underwent clinical and neuropsychological assessments, magnetic resonance imaging to measure gray matter volumes, and high-resolution positron emission tomography to measure beta-amyloid (Aβ) deposition. Clinical and neuropsychological assessments were repeated after 10-12 weeks of Citalopram or Sertraline treatment (LLD patients only). LLD patients did not differ from healthy controls in baseline neuropsychological function, although patients improved in both depressive symptoms and visual-spatial memory during treatment. Greater Aβ in the left parietal cortex was observed in LLD patients compared with controls. Greater Aβ was correlated with greater depressive symptoms and poorer visual-spatial memory, but not with improvement with treatment. The study of LLD patients with prospective measurements of mood and cognitive responses to antidepressant treatment is an opportunity to understand early neurobiological mechanisms underlying the association between depression and subsequent cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.